BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Skin cancer AND STAT5B, STAT5, 6777, ENSG00000173757, P51692 AND Treatment
25 results:

  • 1. Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma.
    Khushalani NI; Vassallo M; Goldberg JD; Eroglu Z; Kim Y; Cao B; Ferguson R; Monson KR; Kirchhoff T; Amato CM; Burke P; Strange A; Monk E; Gibney GT; Kudchadkar R; Markowitz J; Brohl AS; Pavlick A; Richards A; Woods DM; Weber J
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450385
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study.
    Wang L; Rocas D; Dalle S; Sako N; Pelletier L; Martin N; Dupuy A; Tazi N; Balme B; Vergier B; Beylot-Barry M; Carlotti A; Bagot M; Battistella M; Chaby G; Ingen-Housz-Oro S; Gaulard P; Ortonne N
    Br J Dermatol; 2022 Dec; 187(6):970-980. PubMed ID: 35895386
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Jak-STAT Inhibition Mediates Romidepsin and Mechlorethamine Synergism in Cutaneous T-Cell Lymphoma.
    Cortes JR; Patrone CC; Quinn SA; Gu Y; Sanchez-Martin M; Mackey A; Cooke AJ; Shih BB; Laurent AP; Trager MH; Ferrando AA; Geskin LJ; Palomero T
    J Invest Dermatol; 2021 Dec; 141(12):2908-2920.e7. PubMed ID: 34089720
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Identification of Potential Biomarkers for Anti-PD-1 Therapy in Melanoma by Weighted Correlation Network Analysis.
    Wang X; Chai Z; Li Y; Long F; Hao Y; Pan G; Liu M; Li B
    Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32316408
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. A self-designed CpG ODN enhanced the anti-melanoma effect of pimozide.
    Jia H; Guo J; Wang P; Sun K; Chen J; Ren W; Wei T; Yang Y; Li J; Liu X; Li R; Zhong J; Wang M; Tian Z; Feng Z; Zhao T
    Int Immunopharmacol; 2020 Jun; 83():106397. PubMed ID: 32220805
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Therapeutic melanoma vaccine with cancer stem cell phenotype represses exhaustion and maintains antigen-specific T cell stemness by up-regulating BCL6.
    Czerwinska P; Rucinski M; Wlodarczyk N; Jaworska A; Grzadzielewska I; Gryska K; Galus L; Mackiewicz J; Mackiewicz A
    Oncoimmunology; 2020; 9(1):1710063. PubMed ID: 32002306
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node.
    Leiter U; Stadler R; Mauch C; Hohenberger W; Brockmeyer NH; Berking C; Sunderkötter C; Kaatz M; Schatton K; Lehmann P; Vogt T; Ulrich J; Herbst R; Gehring W; Simon JC; Keim U; Verver D; Martus P; Garbe C;
    J Clin Oncol; 2019 Nov; 37(32):3000-3008. PubMed ID: 31557067
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Effects of 9-cis-retinoic acid on the proliferation and apoptosis of cutaneous T-cell lymphoma cells.
    Yang H; Tao Y; Zhang M; Ma P; Li L; Diao Q
    Anticancer Drugs; 2019 Jan; 30(1):56-64. PubMed ID: 30198914
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. The enhanced antitumour response of pimozide combined with the IDO inhibitor L‑MT in melanoma.
    Jia H; Ren W; Feng Y; Wei T; Guo M; Guo J; Zhao J; Song X; Wang M; Zhao T; Wang H; Feng Z; Tian Z
    Int J Oncol; 2018 Sep; 53(3):949-960. PubMed ID: 30015838
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype.
    Ohanna M; Cerezo M; Nottet N; Bille K; Didier R; Beranger G; Mograbi B; Rocchi S; Yvan-Charvet L; Ballotti R; Bertolotto C
    Genes Dev; 2018 Mar; 32(5-6):448-461. PubMed ID: 29567766
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activation.
    Xiao Q; Wu J; Wang WJ; Chen S; Zheng Y; Yu X; Meeth K; Sahraei M; Bothwell ALM; Chen L; Bosenberg M; Chen J; Sexl V; Sun L; Li L; Tang W; Wu D
    Nat Med; 2018 Mar; 24(3):262-270. PubMed ID: 29431745
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. ECPIRM, a Potential Therapeutic Agent for Cutaneous T-Cell Lymphoma, Inhibits Cell Proliferation and Promotes Apoptosis via a JAK/STAT Pathway.
    Yang H; Ma P; Cao Y; Zhang M; Li L; Wei J; Tao L; Qian K
    Anticancer Agents Med Chem; 2018; 18(3):401-411. PubMed ID: 28356009
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. STAT3/5-Dependent IL9 Overexpression Contributes to Neoplastic Cell Survival in Mycosis Fungoides.
    Vieyra-Garcia PA; Wei T; Naym DG; Fredholm S; Fink-Puches R; Cerroni L; Odum N; O'Malley JT; Gniadecki R; Wolf P
    Clin Cancer Res; 2016 Jul; 22(13):3328-39. PubMed ID: 26851186
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Emergence of clonal hematopoiesis in the majority of patients with acquired aplastic anemia.
    Babushok DV; Perdigones N; Perin JC; Olson TS; Ye W; Roth JJ; Lind C; Cattier C; Li Y; Hartung H; Paessler ME; Frank DM; Xie HM; Cross S; Cockroft JD; Podsakoff GM; Monos D; Biegel JA; Mason PJ; Bessler M
    Cancer Genet; 2015 Apr; 208(4):115-28. PubMed ID: 25800665
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders.
    Velusamy T; Kiel MJ; Sahasrabuddhe AA; Rolland D; Dixon CA; Bailey NG; Betz BL; Brown NA; Hristov AC; Wilcox RA; Miranda RN; Medeiros LJ; Jeon YK; Inamdar KV; Lim MS; Elenitoba-Johnson KS
    Blood; 2014 Dec; 124(25):3768-71. PubMed ID: 25349176
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.
    Monk P; Lam E; Mortazavi A; Kendra K; Lesinski GB; Mace TA; Geyer S; Carson WE; Tahiri S; Bhinder A; Clinton SK; Olencki T
    J Immunother; 2014 Apr; 37(3):180-6. PubMed ID: 24598448
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Human metastatic melanoma cell lines express high levels of growth hormone receptor and respond to GH treatment.
    Sustarsic EG; Junnila RK; Kopchick JJ
    Biochem Biophys Res Commun; 2013 Nov; 441(1):144-50. PubMed ID: 24134847
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. t(8;9)(p22;p24)/PCM1-JAK2 activates SOCS2 and SOCS3 via stat5.
    Ehrentraut S; Nagel S; Scherr ME; Schneider B; Quentmeier H; Geffers R; Kaufmann M; Meyer C; Prochorec-Sobieszek M; Ketterling RP; Knudson RA; Feldman AL; Kadin ME; Drexler HG; MacLeod RA
    PLoS One; 2013; 8(1):e53767. PubMed ID: 23372669
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
    Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P
    Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Curcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines.
    Bill MA; Bakan C; Benson DM; Fuchs J; Young G; Lesinski GB
    Mol Cancer Ther; 2009 Sep; 8(9):2726-35. PubMed ID: 19723881
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.